Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.31 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555231 | 1.00 | SCN4A (0.40) | SCN4ATACR1SLC6A4HSD11B1MLNR | |
| SCHEMBL26364532 | 0.89 | SCN4A (0.44) | SCN4ATACR1SLC6A4MLNRHRH3 | |
| SCHEMBL26364558 | 0.77 | SCN4A (0.58) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL26364702 | 0.77 | SCN4A (0.58) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL29517131 | 0.77 | SCN4A (0.58) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL26256073 | 0.74 | SCN4A (0.42) | SCN4ASLC6A4HTR2CHTR2B | |
| SCHEMBL26364480 | 0.73 | SCN4A (0.53) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL2170010 | 0.71 | HTR2C (0.39) | SCN4AMLNRHTR2CHTR2BKCNH2 | |
| SCHEMBL26364459 | 0.69 | MLNR (0.51) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL26364663 | 0.69 | MLNR (0.51) | SCN4AMLNRPFKFB2PFKFB1PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4188918-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022026565-A9 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022026565-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303510-A1 | CYCLIZED ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLB, POLH | SCN4A 3727/4885TACR1 4792/4885SLC6A4 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.